Paramount stock tumbles on Warner deal worries

Paramount shares fell sharply on Wednesday as investors grew more cautious about the company’s proposed acquisition of Warner Bros. Discovery, with fresh regulatory and legal pressure adding to concerns that the deal could take longer, cost more or face tougher conditions.

The stock dropped by as much as 9% during the session, according to market reports, as traders weighed scrutiny from the European Union and the United Kingdom, along with signs that state attorneys general may move against the transaction. Paramount has said the European Commission has until July 22 to complete its review, with a possible 10-day extension if remedies are proposed.

Why investors are reacting

The deal is already under review by multiple regulators, and the latest wave of concern centers on whether the process could slip into a longer or more contested phase. That matters because the acquisition is large, politically sensitive and likely to face demands for concessions in at least some jurisdictions.

The European review has become a key marker for the market. Paramount has offered concessions to Brussels, and the company says the current review deadline is July 22. A 10-day extension remains possible if the commission asks for remedies.

In the UK, Culture Secretary Lisa Nandy has signaled that the government is minded to intervene, citing media plurality and competition concerns. The review there is still active.

Legal and regulatory pressure

State-level opposition is also in focus. An Oregon attorney general has requested a court-ordered 60-day delay to review deal-related records, and a coalition of state attorneys general is expected to file a lawsuit opposing the merger.

Paramount said the Oregon request has not changed its closing timeline. That statement helped frame the day’s tension: the company is pushing back on the idea that the transaction has been derailed, while investors are pricing in the possibility of delay.

The competing messages underscore how much the market is now focused on process risk rather than the strategic logic of the deal itself.

What happens next

The immediate milestones are regulatory rather than financial. Investors are watching for any European Commission action by July 22, including whether regulators demand remedies. They are also waiting to see whether state attorneys general formally file suit.

For now, Paramount is arguing that the transaction remains on track. The market, however, is signaling that the path to closing is becoming more complicated.